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INTRODUCTION
India is the major contributor to malaria burden in
Southeast Asia1. In a recent study by “million death col-
laboration”, it was estimated that malaria accounts for
205,000 deaths per year in India, with 55,000 deaths oc-
curring in early childhood2. These numbers though have
been questioned by some3 as they do highlight that the
problem is much more than previously presumed.
Malaria due to P. falciparum has been historically
associated with severe complications and mortality. How-
ever, P. vivax is now increasingly being reported as a cause
of severe malaria from countries across the globe. Un-
usual manifestations like glomerulonephritis and gastro-
enteritis have also been reported4–5.
This study was planned with the objectives to study
the profile of malarial admissions in a tertiary care pedi-
atric  (<12 yr age) hospital of northern India and to assess
the contribution of P. vivax infection to the morbidity and
mortality.
MATERIAL & METHODS
This retrospective study was conducted at a pediatric
tertiary care hospital located at New Delhi, India. This is
a referral centre for children up to 12-yr of age and re-
ceives patients from Delhi and its surrounding states. The
data pertaining to inpatient cases of malaria were collected
for the entire year 2011. For enlisting of cases, central
registration numbers were obtained from the medical
records department (using ICD-10 codes) and from the
laboratory (cases with peripheral smear positive for ma-
laria and/or positive rapid malaria antigen test). A final list
of cases was compiled from two sources and the electronic
scanned case records were retrieved and reviewed. De-
tailed clinical, biochemical and hematological character-
istics along with the course of hospital stay of each case
record was entered in a pre-designed proforma and trans-
ferred to a Microsoft Excel sheet. The laboratory data
mentioned in the case records were cross-checked directly
with the laboratory records for each patient. The rapid
malaria antigen kit used at the study centre was based on
detection of lactate dehydrogenase and histidine-rich pro-
tein-2.
In the final analysis, only cases with clinical picture
consistent with malaria along with presence of malarial
parasite on peripheral smear and/or positive rapid ma-
larial antigen test (from the hospital laboratory or outside
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ABSTRACT
Background & objectives: Vivax malaria has long been considered a benign entity. However, an increasing number
of reports are highlighting that it may no longer be so. An investigation was carried out to study the profile of
malarial admissions in a tertiary care pediatric hospital and to analyse the burden of vivax-related complications.
Methods: It is a retrospective observational study.  The medical case records of all the patients admitted in the
year 2011 with the clinical diagnosis of malaria and laboratory evidence in the form of positive peripheral smear
and/or rapid malarial antigen test were retrieved and retrospectively analysed.
Results: Overall, 198 cases were included, 128 (64.6%) were due to Plasmodium vivax, 66 (33.3%) due to P.
falciparum and 4 (2%) had evidence of mixed infection of Pv + Pf. The clinical features on admission were
similar in all the groups. In total, 64/128 (50%) patients with vivax infection had one or more complications with
severe anemia in 33 (26%) and cerebral malaria in 16 (12.5%). Six deaths were reported in P. vivax cases. In the
falciparum group, 52 (78.8%) had one or more complications with severe anemia in 37 (56.1%) and cerebral
malaria in 24 (36.4%). Four deaths were reported in P. falciparum cases.
Interpretation & conclusion: Overall because of their larger numbers, vivax patients outnumbered other groups,
with regards to severe complications and deaths. It was concluded that vivax malaria is emerging as an important
cause of malaria-related complications in children.
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laboratory, in case, the patient was referred with an es-
tablished diagnosis) were included. Thus, those with clini-
cal diagnosis of malaria but without any evidence on smear
or antigen testing were not included.
Based on the results of peripheral smear and/or rapid
malaria test, the cases were categorized into three groups:
vivax malaria, falciparum malaria and mixed (Pv +Pf) ma-
laria. Complications such as cerebral malaria, acute renal
failure (ARF), shock, severe anaemia and hypoglycemia
were defined as per WHO guidelines6. Hepatitis was de-
fined as patients having clinical jaundice and conjugated
hyperbilirubinemia with or without raised enzyme levels
and negative viral studies. Severe thrombocytopenia was
defined as platelet count <20,000/mm3 and disseminated
intravascular coagulation (DIC) was defined as patients
with clinical features of bleeding with presence of
coagulopathy (prolonged prothrombin time and activated
partial thromboplastin time) and thrombocytopenia.
In addition, patients with raised urea (>50 mg%) and
creatinine levels (<3 mg/dl), which subsequently im-
proved without any specific intervention, were defined
as having prerenal azotemia. Hyponatremia and
hypernatremia were defined as serum sodium <130 meq/l
and >150 meq/l, respectively. Hypokalemia was defined
as serum potassium <3.5 meq/l and hyperkalemia as >5.5
meq/l. The complications that could be attributed to non-
malarial etiologies were excluded from the data.
Other investigations were carried out to rule out co-
existing conditions, depending on the clinical situation.
Patients received treatment for malaria as per WHO guide-
lines6. Supportive treatment was given as per the depart-
mental protocols. The study protocol was approved by
the institutional scientific committee. The data were ana-
lyzed using Epi Info version 3.1. The median and
interquartile ranges were reported for continuous vari-
ables. Proportions were reported for categorical variables
and to detect statistically significant difference between
the groups, Kruskal-Wallis test was used for continuous
variables (medians) and chi-square test for categorical
variables (proportions).
RESULTS
A total of 211 case records of the year 2011 with
clinical/laboratory diagnosis of malaria were retrieved.
In 13 cases, clinical diagnosis of malaria was made but
those lacked laboratory evidence, therefore, the remain-
ing 198 cases were analyzed. The median age was 48
months with range of 1–144 months, 117 (59.1%) chil-
dren were in the age range of 0–5 yr and 119 (60.1%)
were males. A total of 114 (57.6%) patients were resi-
dents of Delhi, whereas 82 (41.4%) were from the
neighbouring state of Uttar Pradesh. Most of the cases
(93.5%) were admitted during the months of June
and October. Peripheral smears were available in
173 (87.4%) patients and were positive in 140 (70.7%)
patients. The rapid malaria antigen test was done in
183 (92.4%) patients and found positive in 173 (87.4%)
patients where 128 (64.6%) patients had vivax malaria,
66 (34.3%) had falciparum malaria and 4 (2%) had mixed
infection.
The median age at presentation was significantly
lower in vivax group (42 months) as compared to
falciparum group (60 months). Also the proportion of
males was more in the vivax group (64%) than falciparum
group (50%). Fever was present in all the cases except
for one neonate with vivax infection. With regard to the
frequency of most of the clinical manifestations, there
was no statistically significant difference among three
groups except for altered sensorium which was more com-
mon in falciparum group.
The complications seen in the three groups are sum-
marized in Table 1. Overall, 118 (59.6%) patients had
severe complication, out of which 76 (64.4%) were in the
age range of 0–5 yr. The proportion of cases with severe
complications was significantly more in the falciparum
group (78.8% as compared to 50% each in vivax and
mixed group). However, the actual number of patients
with severe complications in vivax group was more than
the combined numbers in other two groups (Table 1).
Severe anaemia, cerebral malaria, and acute respiratory
distress syndrome (ARDS) were significantly more com-
mon in the P. falciparum group.
In one patient with altered sensorium and evidence
of hepatitis, hepatitis B surface antigen was found posi-
tive, with raised hepatitis B antigen levels. As these mani-
festations could be due to hepatitis B, the same were not
taken as complications of malaria. Apart from cases with
cerebral malaria, eight patients had seizures, which were
considered to be febrile seizures. Lumbar puncture re-
ports were available in 18 patients with cerebral malaria.
Four showed lymphocytic pleocytosis and in five cases
proteins were elevated. Eight cases were diagnosed as
acute renal failure and received hemodialysis or perito-
neal dialysis. Seven out of these eight were from vivax
group. Ten patients died and in 18 cases outcome was not
known. Eight out of 10 deaths occurred in children of
0–5 yr age group. Mortality rate was more in the
falciparum group, though the absolute numbers of deaths
were more in the vivax group. All the patients who died
had multiple severe complications. Cerebral malaria was
present in 8 out of 10 patients who died. 117 Mittal et al: Malaria in children
DISCUSSION
The present study showed that P. vivax is a signifi-
cant cause of morbidity and mortality in pediatric age
group. Although the complication rate is more in
falciparum infection, vivax is responsible for more than
half of the severe malaria cases. The spectrum of compli-
cations seen in vivax infection is same as of falciparum
infection.
Since, time immemorial P. vivax has been consid-
ered a benign entity and hence the term ‘benign tertian
malaria’ has been used to describe it. However, recent
studies are challenging this term7–11. Studies from north-
ern India and Pakistan showed that 40–64% malarial ad-
missions are accounted by vivax malaria with severe dis-
ease in 30–63% of these patients, which is consistent with
the results of the present study7–11. Studies done in other
countries have also shown that P. vivax can cause severe
malaria, though the proportion of cases with P. vivax in-
fection was much less12–14.
The basic mechanism underlying the complications
in both the vivax and falciparum malaria is similar but
the degree of contribution by the individual multiple fac-
tors differs. Complications such as cerebral malaria, re-
nal failure, hepatic involvement and ARDS are believed
to be due to sequestration of infected red cells in microvas-
culature. Other complications such as severe anaemia, dis-
seminated intravascular coagulation and thrombocytope-
nia are considered to be non-sequestration related with a
multifactorial etiology, e.g. hemolysis of infected and
uninfected red cells, reduced red cell deformability, de-
creased platelet survival and increased uptake15–18.
Involvement of central nervous system in benign
tertian malaria is known to occur since year 192119. There
have been incidental reports since then with the last de-
cade seeing an ever increasing number. In the present
study, 16 (12.5%) cases with P. vivax monoinfection had
cerebral malaria. In the studies from Bikaner and New
Delhi, cerebral malaria was reported in 21.5 and 16.8%
of children with severe vivax malaria, respectively8–9.
Anaemia has been widely observed in both vivax and
falciparum malaria. In our study, severe anaemia was sig-
nificantly more common in the falciparum group than the
vivax group. This has been observed in other studies also.
This may be because the vivax cases generally have lower
parasite densities and, therefore, the likelihood of having
profound anaemia is less18.
Renal manifestations of malaria can range from pre-
renal azotemia to acute renal failure, nephrotic syndrome
and acute glomerulonephritis20–22. In a study from
Karachi, Pakistan, 36 of 75 children with acute malaria
had prerenal azotemia, 30% of which were owing to P.
vivax. No case had ARF10. In the present study, prerenal
azotemia was present in almost half of the P. falciparum
group and about one-fourth of the vivax group. Interest-
ingly, in the present study, seven cases of vivax group
and only one of falciparum group had renal failure re-
quiring dialysis.
Table 1. Complications and mortality among three groups
Severe complication No. of vivax No. of falciparum Mixed p-value
group (n=128) group (n=66) group (n=4)
Cerebral malaria 16 (12.5) 24 (36.4) 1 (25) <0.001
Severe anaemia 33 (25.8) 37 (56.1) 1 (25) <0.001
Severe thrombocytopenia 13 (10.2) 9 (13.6) 0 (0) 0.59
Hepatitis 14 (11.1) 12 (16.7) 1 (25) 0.43
DIC 3 (2.3) 2 (3) 0 (0) 0.90
Acute renal failure 7 (5.5) 1 (1.5) 0 (0) 0.38
Hypoglycemia 0 (0) 1 (1.5) 0 (0) 0.36
ARDS 1 (0.8) 5 (7.6) 0 (0) 0.03
Shock 10 (7.8) 8 (12.1) 0 (0) 0.50
Respiratory failure 7 (5.5) 9 (13.6) 0 (0) 0.11
MODS 4 (3.1) 2 (3) 0 (0) 0.93
Cases with one or more complication 64 (50) 52 (78.8) 2 (50) <0.001
Other complications
Prerenal azotemia 29 (22.7) 30 (45.5) 0 (0) 0.001
Hyperglycemia 0 (0) 2 (2.9) 0 (0) 0.13
Hypokalemia 4 (3.1) 3 (4.5) 0 (0) 0.81
Hyponatremia 3 (2.3) 2 (3.0) 0 (0) 0.90
Coagulopathy 6 (4.7) 6 (9.1) 1 (25) 0.29
Mortality 6 (4.7) 4 (6.1) 0 (0) 0.82
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In the present study, severe thrombocytopenia and
DIC was present in both the vivax and falciparum groups
in almost equal proportions. Although, profound throm-
bocytopenia is considered uncommon in vivax malaria,
recent articles are reporting this with increasing fre-
quency7–9, 12. Further, six out of 10 malarial deaths were
due to P. vivax, which is indeed an important finding. In
the pediatric study from Bikaner, deaths occurred in 4/65
children of the vivax group, as compared to 6/79 of
falciparum group7. Deaths due to vivax malaria have been
reported in significant numbers in other studies also9.
This study had certain limitations, such as species
confirmation was not made by further tests like poly-
merase chain reaction (PCR) and parasite density was also
not estimated. Species-specific PCR increases the diag-
nostic accuracy and can detect submicroscopic infections.
However, it was not available in our research. This study
also represents only those cases of malaria that were ad-
mitted into the hospital. Thus, the complication rates can-
not be generalized to the population at large. The major
strengths of this study were the strict defining criteria for
cerebral malaria, renal failure and other severe complica-
tions. Our data also have probably the largest number of
cases in a single year.
To conclude that P. vivax is emerging as an important
cause of malarial morbidity and mortality. There is a need to
strengthen our strategies to combat this growing menace.
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